Approved to treat different types of advanced non–small cell lung cancer (NSCLC) with certain EGFR mutations

Select a type of lung cancer treatment

EGFR+ NSCLC, 1st treatment

For tumors with exon 19 deletions or exon 21 L858R mutations

EGFR+ NSCLC, 2nd treatment

For tumors with exon 19 deletions or exon 21 L858R mutations

EGFR+ NSCLC with exon 20 insertion mutations, 1st treatment

EGFR+ NSCLC with exon 20 insertion mutations, 2nd treatment

Not sure which of the options above to select?

Ask your doctor and learn more about the types of lung cancer RYBREVANT^® is approved to treat.

Learn about the options

Videos

Real stories from people treated with RYBREVANT^®

Jimmy’s Story

Meet Jimmy, a patient treated with RYBREVANT^®. Hear about his experience and why sharing his story is important to him.

Doctor Discussion Guide

Tips and example questions for having a helpful discussion with your doctor.

Download now

Savings & Support

Once prescribed a RYBREVANT^®-based treatment, connect with a Care Navigator for your support needs.

The support and resources provided by RYBREVANT withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.

EGFR = epidermal growth factor receptor